Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · November 16, 2023

Safety and Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria

Journal of Allergy and Clinical Immunology

 

Additional Info

Journal of Allergy and Clinical Immunology
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
J. Allergy Clin. Immunol 2023 Oct 20;[EPub Ahead of Print], V Jain, A Giménez-Arnau, K Hayama, A Reich, W Carr, J Tillinghast, S Dahale, K Lheritier, P Walsh, A Zharkov, S Hugot, S Haemmerle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading